Eli Lilly Boosts Indiana Investment to $21 Billion with New $4.5 Billion Funding
LLY•Eli Lilly will add $4.5 billion to its Lebanon, Indiana manufacturing campus, bringing total state investments since 2020 to over $21 billion to expand API and genetic medicine production. The funding targets upgrades at Lebanon API and the newly opened Advanced Therapies facility to support drugs like Foundayo, retatrutide, Zepbound and Mounjaro.
1. Investment Details
Eli Lilly is adding $4.5 billion to its Lebanon, Indiana manufacturing campus, boosting total Indiana investments since 2020 to more than $21 billion. Across the U.S., Lilly has invested over $50 billion in domestic facility expansions during the same period.
2. Facility Upgrades
The capital will upgrade the Lebanon API site and equip the newly commissioned Lebanon Advanced Therapies facility, Lilly’s first dedicated genetic medicine plant. The Advanced Therapies unit is designed for both clinical research and large-scale commercial production of genetic therapies using novel manufacturing techniques.
3. Production Pipeline
Future production plans at Lebanon API include Foundayo, the recently approved oral weight loss pill, and retatrutide, an investigational therapy for obesity and cardiometabolic disease, alongside Zepbound and Mounjaro injectables. When it opens in 2027, Lebanon API will be the largest API production site in U.S. history.
4. Economic and Timeline Impact
Construction on the expanded facilities is expected to begin before year-end, with operations ramping up thereafter. Lilly accounts for 70% of Indiana’s pharmaceutical GDP, and each Lilly position supports more than two additional jobs in the state.
